SAMSUNG PHARMACEUTICAL.CO.,Ltd.
Financials
Valuation Metrics
SAMSUNG PHARMACEUTICAL.CO.,Ltd.'s Market Cap is ₩1243B. At end of 2025 it was ₩1441B. Ranked #1100 of 2,436 in KR market (top 45%), #537 of 787 on KOSPI (top 68%), #129 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 124.29B KRW | KR#1,100/2,436 Sec#129/234 |
| Revenue | 43.73B KRW | KR#1,846/2,436 Sec#128/234 |
| Net Income | -16.94B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 175.35B KRW | KR#1,366/2,436 Sec#103/234 |
| Net Assets | 129.81B KRW | KR#1,206/2,436 Sec#96/234 |
| Employees | 86 | KR#1,741/2,436 Sec#137/234 |
| Value | ||
| P/B | 0.96x | KR#1,433/2,436 Sec#92/234 |
| P/S | 2.84x | KR#1,989/2,436 Sec#122/234 |
| FCF Yield | -8.13% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -13.05% | KR#1,952/2,436 Sec#152/234 |
| ROA | -9.66% | KR#2,067/2,436 Sec#158/234 |
| Op. Margin | -35.37% | KR#2,199/2,436 Sec#157/234 |
| Revenue Growth | -20.62% | KR#2,077/2,436 Sec#189/234 |
| Earnings Growth | -76.46% | KR#1,300/2,436 Sec#86/234 |
| Financial Health | ||
| Debt Ratio | 135.08% | KR#946/2,436 Sec#111/234 |
| Total Debt | 21.85B KRW | KR#1,327/2,436 Sec#109/234 |
| FCF | -10.10B KRW | KR#1,713/2,436 Sec#149/234 |
| Cash | 8.00B KRW | KR#1,796/2,436 Sec#153/234 |
| Current Ratio | 0.96x | KR#1,861/2,436 Sec#185/234 |
| Performance | ||
| 1Y Return | -15.38% | KR#1,190/2,436 Sec#96/234 |
| 1M Return | -3.23% | KR#1,411/2,436 Sec#129/234 |
| From 52W High | -43.10% | KR#947/2,436 Sec#72/234 |
| 1Y MDD | -46.61% | KR#770/2,436 Sec#65/234 |
| Trading | ||
| Volume | 491,090 shares | KR#463/2,436 Sec#39/234 |
| Foreign Own. | 2.99% | KR#999/2,436 Sec#98/234 |
| Per Share | ||
| EPS | -180 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,379 KRW | KR#2,193/2,436 Sec#195/234 |
Company Info
Samseong Pharmaceutical was founded as Samseong Pharmaceutical Office in 1929, incorporated in 1954, and listed on the KOSPI market in 1975. The company operates in pharmaceutical manufacturing and sales, bio business, and health food sales, holding 11 affiliated companies including its largest shareholder, GemVax & KAEL Co., Ltd. It markets over 80 product groups of specialized prescription drugs, such as antibiotics and prostate treatment drugs, via CSO marketing. Over-the-counter drugs like Kkasmyeongsu and Panto-A are supplied to pharmacies and convenience stores through an exclusive agreement with Jeil Health Science. Samseong Pharmaceutical is headquartered in Hwaseong, Gyeonggi Province.